InnoCare Starts China Trial of SHP2 Inhibitor for Solid Tumors
publication date: Jun 22, 2022
Beijing InnoCare has dosed the first patient in a China clinical trial of its novel SHP2 allosteric inhibitor in patients with solid tumors. SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) is involved in mediating the MAPK signaling pathway and immune checkpoint pathway, regulating cellular proliferation and survival. In preclinical studies, the candidate, ICP-189, showed better selectivity than other phosphatases and produced significant anti-tumor effects in various xenograft models, according to InnoCare. Founded in 2015, InnoCare is developing novel drugs for cancer and autoimmune diseases. More details....
Stock Symbol: (HK: 09969)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.